Sagimet Biosciences (SGMT) Competitors $2.22 -0.06 (-2.42%) Closing price 03:59 PM EasternExtended Trading$2.22 +0.01 (+0.23%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. AVIR, ESPR, SLRN, CADL, SLDB, ACB, PVLA, IMMP, OLMA, and CMPXShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Atea Pharmaceuticals (AVIR), Esperion Therapeutics (ESPR), Acelyrin (SLRN), Candel Therapeutics (CADL), Solid Biosciences (SLDB), Aurora Cannabis (ACB), Palvella Therapeutics (PVLA), Immutep (IMMP), Olema Pharmaceuticals (OLMA), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Atea Pharmaceuticals Esperion Therapeutics Acelyrin Candel Therapeutics Solid Biosciences Aurora Cannabis Palvella Therapeutics Immutep Olema Pharmaceuticals Compass Therapeutics Sagimet Biosciences (NASDAQ:SGMT) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Does the media prefer SGMT or AVIR? In the previous week, Atea Pharmaceuticals had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Atea Pharmaceuticals and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.96 beat Atea Pharmaceuticals' score of 0.85 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Overall Sentiment Sagimet Biosciences Positive Atea Pharmaceuticals Positive Do analysts recommend SGMT or AVIR? Sagimet Biosciences presently has a consensus target price of $22.40, suggesting a potential upside of 886.78%. Atea Pharmaceuticals has a consensus target price of $6.88, suggesting a potential upside of 151.09%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, SGMT or AVIR? Sagimet Biosciences has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Is SGMT or AVIR more profitable? Sagimet Biosciences' return on equity of -23.63% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% Atea Pharmaceuticals N/A -34.90%-32.38% Do institutionals & insiders hold more shares of SGMT or AVIR? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better valuation & earnings, SGMT or AVIR? Sagimet Biosciences has higher revenue and earnings than Atea Pharmaceuticals. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M34.82-$27.88M-$1.43-1.59Atea PharmaceuticalsN/AN/A-$135.96M-$2.00-1.37 Does the MarketBeat Community believe in SGMT or AVIR? Sagimet Biosciences received 8 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 96.43% of users gave Sagimet Biosciences an outperform vote while only 48.72% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2796.43% Underperform Votes13.57%Atea PharmaceuticalsOutperform Votes1948.72% Underperform Votes2051.28% SummarySagimet Biosciences beats Atea Pharmaceuticals on 13 of the 16 factors compared between the two stocks. Remove Ads Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.63M$6.27B$5.29B$7.60BDividend YieldN/A2.98%5.35%4.27%P/E Ratio-1.596.8322.2218.06Price / Sales34.82200.79362.6890.67Price / CashN/A65.6738.1534.64Price / Book0.575.646.283.95Net Income-$27.88M$140.88M$3.19B$247.18M7 Day PerformanceN/A0.22%-1.53%-0.72%1 Month Performance-35.88%-10.02%-0.57%-6.01%1 Year Performance-55.14%-17.16%5.07%-3.92% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.6511 of 5 stars$2.22-2.4%$22.40+911.3%-57.3%$67.95M$2M-1.558AVIRAtea Pharmaceuticals2.5351 of 5 stars$2.78-0.4%$6.88+147.5%-28.1%$237.76MN/A-1.3470News CoverageGap DownESPREsperion Therapeutics3.6097 of 5 stars$1.20-2.4%$6.75+462.5%-62.4%$237.42M$332.31M-1.88200Analyst ForecastNews CoverageGap DownSLRNAcelyrin2.8687 of 5 stars$2.31-4.9%$9.60+315.6%-63.5%$232.64MN/A-0.94135Gap DownCADLCandel Therapeutics2.0701 of 5 stars$4.84+0.4%$21.00+333.9%+0.0%$228.62M$120,000.00-2.8060Gap DownSLDBSolid Biosciences3.3862 of 5 stars$2.94-5.8%$15.67+432.9%-76.3%$227.83M$8.09M-0.97100Positive NewsACBAurora Cannabis0.3972 of 5 stars$4.05+1.0%N/A-33.0%$227.67M$320.81M81.021,340Gap DownPVLAPalvella Therapeutics3.0827 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/AAnalyst ForecastGap DownIMMPImmutep1.5448 of 5 stars$1.42-5.3%$8.50+498.6%-43.8%$218.34M$5.14M0.002,021Gap UpOLMAOlema Pharmaceuticals2.3156 of 5 stars$3.18-2.2%$27.67+770.0%-72.7%$217.30MN/A-1.4570Positive NewsGap DownCMPXCompass Therapeutics3.3506 of 5 stars$1.57+7.5%$13.38+751.9%+4.8%$217.10M$850,000.00-4.2420Gap Down Remove Ads Related Companies and Tools Related Companies Atea Pharmaceuticals Competitors Esperion Therapeutics Competitors Acelyrin Competitors Candel Therapeutics Competitors Solid Biosciences Competitors Aurora Cannabis Competitors Palvella Therapeutics Competitors Immutep Competitors Olema Pharmaceuticals Competitors Compass Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 4/10/2025 by MarketBeat.com Staff From Our Partners6 stocks could soar on DOGE AI news …Stay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SGMT Stock Free SGMT Stock Alerts